FDA approves meningococcal vaccine

The U.S. Food and Drug Administration has approved the use of a vaccine protecting against five meningococcal serogroups in adolescent and young adult patients.

The novel vaccine was designed to target the A, B, C, W and Y serogroups of Neisseria meningitidis, according to a report from Pharmacy Times. FDA approval followed positive findings from two phase III trials — which examined the vaccine’s safety, tolerability and immunogenicity.

Researchers found that the vaccine had a safety profile consistent with existing meningococcal vaccines and effectively reduced the number of required injections. They hope the FDA approval can help improve meningococcal vaccination coverage, especially in the prevention of invasive meningococcal disease caused by serogroup B.

Read more: Pharmacy Times

The article presented here is intended to inform you about the broader media perspective on dentistry, regardless of its alignment with the ADA's stance. It is important to note that publication of an article does not imply the ADA's endorsement, agreement, or promotion of its content.